Serum macrophage markers track with metastatic prostate cancer and flag a poorer mCRPC course
Circulating markers of macrophage biology are moving from immunology into prostate cancer prognostication. In this British Journal of Cancer study, serum sCD163 and sSIRPα were measured across three prostate cancer cohorts spanning different disease stages, and the pattern was immediately more informative than a simple comparison of localized and metastatic disease. Both markers were significantly higher in patients with metastatic disease than in those with localized prostate cancer. The signal was strongest for a question clinicians have struggled to answer with standard laboratory tests alone: which men with metastatic castration-resistant prostate cancer are likely to progress early on first-line treatment?
The answer, at least for sCD163, was clinically meaningful.
Why macrophage biology matters in advanced prostate cancer
Macrophages sit at the center of the tumor microenvironment, where they can promote immune escape, tissue remodeling, and therapeutic resistance. In prostate cancer, that biology is not abstract. Prior translational work has linked tumor-associated macrophages with high-grade disease, biochemical recurrence, and lethal outcomes, making myeloid signaling an appealing place to look for noninvasive biomarkers. CD163 is commonly tied to an immunosuppressive, M2-like macrophage phenotype, and soluble CD163 reflects shedding from activated macrophages. SIRPα belongs to the same broad immune axis and is involved in macrophage regulation, so its appearance in serum offers another view of the host-tumor interaction.
The present data support the idea that the immune milieu changes as prostate cancer spreads. Serum levels of both markers rose in metastatic disease, which fits the biology of metastatic progression: a tumor that survives dissemination often does so by reshaping the surrounding immune environment, not merely by accumulating tumor cell mutations. A bloodstream assay that captures some of that host response is attractive because it can be repeated over time and does not depend on tissue sampling from a single lesion.
Localized and hormone-sensitive disease showed a weaker prognostic signal
The study did not show a broad prognostic relationship in hormone-sensitive prostate cancer. In that setting, serum sCD163 and sSIRPα were generally not associated with clinical parameters of disease aggressiveness. That finding narrows the role of these markers rather than diminishing it. Early-stage and hormone-sensitive disease are biologically more heterogeneous, and standard clinical features still carry much of the available prognostic weight there. In practice, a biomarker that separates metastatic from localized disease but adds little in hormone-sensitive cohorts may still become useful later in the disease course, where treatment selection and survival prediction are more difficult.
The data also suggest that macrophage marker biology is stage-dependent. A blood marker can be elevated because of tumor burden, inflammatory activity, or both, yet still fail to resolve aggressiveness until the disease reaches a state in which immune escape becomes dominant. That distinction fits the metastatic setting far better than the hormone-sensitive one.
sCD163 identified men at risk for earlier progression on first-line mCRPC therapy
The most clinically actionable result came from metastatic castration-resistant prostate cancer. In both the training cohort and the independent validation cohort, higher serum sCD163 predicted shorter progression-free survival on first-line treatment, even after adjustment for standard clinical parameters. In the training cohort, the hazard ratio was 1.77 with a 95% confidence interval of 1.12 to 2.78 and a p value of 0.014. In the validation cohort, the hazard ratio was 1.85 with a 95% confidence interval of 1.15 to 2.97 and a p value of 0.011.
That consistency across two cohorts matters because it reduces the chance that the result is simply a statistical artifact of one patient set. A marker that remains prognostic after conventional clinical adjustment is more plausible as a future companion to PSA, imaging, and performance status than as a standalone curiosity. Here, the biology and the clinical endpoint align: high soluble CD163 likely reflects a macrophage-rich, immunosuppressive milieu that helps the tumor withstand therapy and re-emerge sooner.
A blood test that could complement existing risk stratification
The appeal of a serum biomarker in mCRPC is straightforward. Patients at this stage often begin first-line therapy with substantial uncertainty about durability of benefit, and current prognostic tools do not fully capture the tumor microenvironment. A minimally invasive marker that mirrors macrophage activation could help separate men with a more inflamed, therapy-resistant disease biology from those with a more favorable course.
Still, the study does not justify immediate routine use. The cohorts were sizable for translational work, with 646 patients across the three prostate cancer cohorts and 161 patients in the independent mCRPC validation group, but these are still biomarker cohorts rather than a practice-changing prospective interventional trial. The work shows association, not clinical utility in a management algorithm. It also does not establish whether serial measurement would improve risk prediction over a single baseline value, or whether treatment changes based on sCD163 would improve outcomes.
What the biomarker signal does and does not prove
The results point toward a real biologic gradient across disease stages, but they do not prove that macrophages drive progression in every patient with high serum CD163. Soluble markers can be influenced by tumor burden, systemic inflammation, and other host factors. Even so, the validation of the prognostic association in mCRPC strengthens the case that this is more than a nonspecific inflammatory readout. It is a marker with a disease-stage pattern and a survival signal attached to it.
Serum sSIRPα also rose in metastatic disease, yet the clearest prognostic finding centered on sCD163. That asymmetry suggests that the macrophage axis is not uniform; different soluble markers may capture different pieces of the same immune process, with one proving more tightly linked to treatment resistance than the other. In translational terms, this is exactly how biomarker development often matures: broad biologic plausibility first, then narrowing to the analyte that best tracks with outcome.
The next step is not larger enthusiasm. It is prospective testing in contemporary mCRPC cohorts, ideally alongside treatment-specific endpoints and serial sampling, to determine whether sCD163 can refine prognostication beyond standard clinicopathologic variables and whether it can do so early enough to influence care.